BMT CTN Protocol 1102

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome.

Below are protocol-related documents, which may be periodically updated.

            Protocol Co-Chair: Ryotaro Nakamura, MD (626-256-4673)

            Protocol Co-Chair: Corey Cutler,MD ()

            Protocol Officer: Wael Saber, MD414-805-0300)

            Protocol Coordinators: Alyssa Ramirez (301-251-1161)

                                                    Garett Skelton

            Medical Monitor: Bipin Savini, MD


The BMT CTN is committed to including widespread transplant community participation in these trials. However, affiliate center applications are not currently being accepted for this study.